Details of the Drug

General Information of Drug (ID: DML0GZ2)

Drug Name

Lead acetate

Synonyms

LEAD ACETATE; Lead diacetate; Lead(II) acetate; Lead(2+) acetate; 301-04-2; Acetic acid, lead salt; Unichem PBA; Lead di(acetate); Normal lead acetate; Dibasic lead acetate; Lead dibasic acetate; Bleiacetat [German]; lead(2+) diacetate; Plumbous acetate; Salt of saturn; Sugar of lead; Caswell No. 523A; Lead acetate (anhydrous); RCRA waste number U144; Acetate de plomb [French]; Lead acetate (Pb(Ac)2); Acetic acid lead(2+) salt; CCRIS 356; Acetic acid, lead(2+) salt; Acetic acid, lead(2 +) salt; UNII-KL498O6790; Acetate de plomb

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

325

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

0

Hydrogen Bond Donor Count

0

Hydrogen Bond Acceptor Count

4

Chemical Identifiers

Formula: C4H6O4Pb
IUPAC Name: lead(2+);diacetate
Canonical SMILES: CC(=O)[O-].CC(=O)[O-].[Pb+2]
InChI: InChI=1S/2C2H4O2.Pb/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
InChIKey: GUWSLQUAAYEZAF-UHFFFAOYSA-L

Cross-matching ID

PubChem CID: 9317
CAS Number: 301-04-2
TTD ID: D0S4VW

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ferrochelatase (FECH)	TTQ6VF4	HEMH_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
60 kDa heat shock protein, mitochondrial (HSPD1)	OTTO1Y11	CH60_HUMAN	Gene/Protein Processing	[2]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[3]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[3]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Gene/Protein Processing	[4]
Arrestin domain-containing protein 4 (ARRDC4)	OTINJ0FX	ARRD4_HUMAN	Gene/Protein Processing	[3]
Aspartyl/asparaginyl beta-hydroxylase (ASPH)	OT3KGDEE	ASPH_HUMAN	Gene/Protein Processing	[3]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[5]
Beta-1,3-galactosyltransferase 2 (B3GALT2)	OTISOEGU	B3GT2_HUMAN	Gene/Protein Processing	[6]
CD59 glycoprotein (CD59)	OTSUMQDH	CD59_HUMAN	Gene/Protein Processing	[7]
Claudin-5 (CLDN5)	OTUX60YO	CLD5_HUMAN	Gene/Protein Processing	[8]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Ferrochelatase, a novel target for photodynamic therapy of cancer. Oncol Rep. 1999 Nov-Dec;6(6):1439-42.
2	Lead (Pb) induced ATM-dependent mitophagy via PINK1/Parkin pathway. Toxicol Lett. 2018 Jul;291:92-100. doi: 10.1016/j.toxlet.2018.04.012. Epub 2018 Apr 13.
3	Analysis of lead toxicity in human cells. BMC Genomics. 2012 Jul 27;13:344.
4	Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. Neuropharmacology. 2014 Apr;79:596-602. doi: 10.1016/j.neuropharm.2014.01.009. Epub 2014 Jan 21.
5	The role of HO-1 in protection against lead-induced neurotoxicity. Neurotoxicology. 2016 Jan;52:1-11. doi: 10.1016/j.neuro.2015.10.015. Epub 2015 Nov 2.
6	In vitro effects of lead on gene expression in neural stem cells and associations between up-regulated genes and cognitive scores in children. Environ Health Perspect. 2017 Apr;125(4):721-729.
7	Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
8	[Changes and regulatory mechanism of tight junction proteins in in vitro model of lead-induced blood-brain barrier injury]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Nov;29(11):1141-6.